Previous close | 2.6500 |
Open | 2.4300 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 2.6500 - 2.6500 |
52-week range | 2.2990 - 3.3700 |
Volume | |
Avg. volume | 27 |
Market cap | 214.231M |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1000 |
Earnings date | 10 May 2024 - 18 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MARSEILLE, France, April 15, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101 (NCT05086315), evaluating SAR443579 as a monotherapy for the treatment of blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia and hig
MARSEILLE, France, April 15, 2024--Innate Pharma to hold its Annual General Meeting of shareholders on May 23, 2024
Innate Pharma (IPHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.